Spago Nanomedical AB (OSTO:SPAGO) ROCE % : -84.89% (As of Mar. 2024)

View and export this data going back to 2012. Start your Free Trial

What is Spago Nanomedical AB ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Spago Nanomedical AB's annualized ROCE % for the quarter that ended in Mar. 2024 was -84.89%.

Spago Nanomedical AB ROCE % Historical Data

The historical data trend for Spago Nanomedical AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spago Nanomedical AB ROCE % Chart

Spago Nanomedical AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-15.46

-12.75

-22.68

-20.47

-35.62

Spago Nanomedical AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															-33.31	-18.12	-17.06	-47.55	-84.89

Spago Nanomedical AB ROCE % Calculation

Spago Nanomedical AB's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-42.505	/	( ( (205.953 - 8.797)	+	(52.985 - 11.477) )	/ 2 )
	=	-42.505	/	( (197.156	+	41.508)	/ 2 )
	=	-42.505	/	119.332
	=	-35.62 %

Spago Nanomedical AB's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-32.276	/	( ( (52.985 - 11.477)	+	(41.468 - 6.933) )	/ 2 )
	=	-32.276	/	( ( 41.508	+	34.535 )	/ 2 )
	=	-32.276	/	38.0215
	=	-84.89 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Spago Nanomedical AB (OSTO:SPAGO) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Spago Nanomedical AB ROCE % Related Terms

Thank you for viewing the detailed overview of Spago Nanomedical AB's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Spago Nanomedical AB (OSTO:SPAGO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spago Nanomedical AB (OSTO:SPAGO) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

7UX:Germany

Address

Scheelevagen 22, Lund, SWE, SE-223 63

Website

https://www.spagonanomedical.se

Spago Nanomedical AB is a nanomedicine company in the field of cancer diagnosis and treatment. The company's product includes SpagoPix and Tumorad. The SpagoPix product aims to improve cancer diagnosis with magnetic resonance imaging through previous detection of tumors and metastases. The Tumorad products focuses on the development of a completely new form of radionuclide therapy for tumor selective radiation therapy of cancer. The company development projects are based on a platform of polymeric materials with varoious properties for precise diagnosis and treatment of life threatening and debilitating diseases.

Spago Nanomedical AB (OSTO:SPAGO) Headlines

No Headlines